Adrixetinib

Tier C — Watch / trade

Adrixetinib

Vichem Chemie

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：AXL, CSF1R, MerTK

Indications (approved)：Hepatocellular carcinoma, Cervical cancer, Oesophageal cancer, Gastric cancer, Graft-versus-host disease, Erdheim-Chester disease, 窦性组织细胞增生症, Myelodysplastic syndrome

Regional status

Phase II

2023-01-12

Phase I

2025-12-23

China

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Adrixetinib?

Approved indications include: Hepatocellular carcinoma, Cervical cancer, Oesophageal cancer, Gastric cancer, Graft-versus-host disease, Erdheim-Chester disease, 窦性组织细胞增生症, Myelodysplastic syndrome.

When does the Adrixetinib patent expire?

No public expiry year is available for Adrixetinib yet; this page updates once verified.

How do I get a quote for Adrixetinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-03